This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, prof. Jukema discusses the use of PCSK9 inhibitors in high risk patients and the recommendations from international guidelines.

Educational information

This educational video is the fourth part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Other topics covered in this series

Other lectures part of this educational series are:

• Identifying patients for PCSK9 therapy - Prof. Kees Hovingh, MD, Amsterdam University Medical Center , The Netherlands
• PCSK9 inhibitors: How do they work? - Prof. John Chapman, Pierre and Marie Curie University, Paris, France
• Landmark trials with PCSK9 inhibitors - Prof. Ph. Gabriel Steg, MD, Hôpital Bichat, Paris, France

Faculty

J. Wouter Jukema, MD, PhD, FESC, FACC, is Professor of Cardiology, an established Clinical Investigator of the Netherlands Heart Foundation, as well as Chairman of “Leiden Vascular Medicine” at Leiden University Medical Center (LUMC) in the Netherlands.

CME Accreditation

For this course, online CME accreditation is applied at EBAC (European Board for Accreditation in Cardiology). Once accredited, the CME program will be available in our CME section

Disclosures

This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.

View slides of prof. Jukema